Physician profile
Ronald Young
NPI 1972522829
$1,507.06
in general payments reported to CMS, 2019-2025
11 companies · $200 in 2025
The $200 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $40.64 · 2021: $97.98 · 2022: $392 · 2023: $239 · 2024: $395 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $302.83 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $300.75 | 2022-2024 | Tyrvaya |
| Alcon Vision LLC | $220.99 | 2019-2025 | Rocklatan, Rhopressa, Eysuvis |
| Abbvie INC. | $215.96 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Bausch & Lomb Americas INC. | $167.08 | 2022-2025 | Vyzulta, Xiidra |
| Tarsus Pharmaceuticals, INC. | $125.43 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $63.56 | 2021-2023 | Acuvue |
| Novartis Pharmaceuticals Corporation | $56.84 | 2019-2020 | |
| Dompe US, INC. | $29.93 | 2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $12.25 | 2021 | |
| Shire North American Group INC | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.